Heart-on-a-chip replicates human drug response: is this the future of cardiac drug development?
An engineered heart-on-a-chip system, developed by TARA Biosystems (NY, USA) and GlaxoSmithKline (London, UK), has been found to reproduce the human heart’s response to known drugs – providing a ground-breaking method for cardiac drug screening.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>